1 / 22

The Cancer Consortium

Why Cancer?. Burden1.4 million new cancer cases in 2008566,000 cancer deathsCostlyCancer treatment ~5% national health expendituresVariation in treatmentSmall efficacy trials can lead to FDA approval of new agents with uncertain effectiveness in the broader populationNot all interventions are

gen
Download Presentation

The Cancer Consortium

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. The Cancer Consortium Deborah Schrag, MD (PI) Caprice Christian Greenberg, MD, MPH Brigham and Womens Hospital Dana-Farber Cancer Institute

    2. Why Cancer? Burden 1.4 million new cancer cases in 2008 566,000 cancer deaths Costly Cancer treatment ~5% national health expenditures Variation in treatment Small efficacy trials can lead to FDA approval of new agents with uncertain effectiveness in the broader population Not all interventions are evaluated with RCTs

    3. The Goals How do we move from the evidence base provided by efficacy trials to non-trial cancer population? Provide expertise in and advance the development of CER in cancer Ensure stakeholder input Assist AHRQ and policymakers in prioritizing cancer-related research

More Related